Navigation Links
Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference
Date:9/9/2009

CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, 2009, at 1:35 p.m. ET at the Grand Hyatt New York.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... ... medications, including anxiolytics, painkillers, antidepressants and cholesterol-lowering drugs, may cause cognitive impairment ... Center —a leading Florida-based drug treatment facility—advises patients to research the potential ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Pregnancy Awareness Month ... trying to conceive. , “If you are ready to have a baby, ... “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy Organizer, written ...
(Date:5/2/2016)... ... , ... TeleMedCo™, a new company developing real time technology ... rapid diagnosis, triage and admission of patients leveraging IBM Watson’s software and healthcare ... the first time at GENBAND’s Perspectives16 conference. , TeleMedCo selected GENBAND’s Kandy ...
(Date:5/2/2016)... N.J. (PRWEB) , ... May 02, 2016 , ... ... Healthcare Research & Analytics EVP and GM Jim Callandrillo and Duane Reed, ... the 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting ...
(Date:5/2/2016)... ... , ... Atlantic Information Services, Inc. (AIS) is pleased to announce its upcoming ... Pharma Landscape .” CMS recently proposed a test of alternate payment models for Medicare ... care provided to beneficiaries. The webinar will review the details of this model, how ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, ... 8 Ireland 7.8 India 7.3, , Source: IMF and TechSci ... comprises of Brazil , Russia , ... Africa , registered the fastest GDP growth during the first decade of ... , recession in Brazil and Russia ...
(Date:5/2/2016)... , May 2, 2016 ... reach USD 11.1 billion by 2024, according to ... Inc. Major drivers of the sonography market include ... and government recommendations for periodic ultrasound screenings of ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) High ...
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
Breaking Medicine Technology: